Ginkgo Bioworks Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Ginkgo Bioworks Holdings

07/08/2026 04:29

Ginkgo Bioworks Holdings, Inc. DNA.N reported a quarterly adjusted loss of 75 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.10.  The mean expectation of two analysts for the quarter was for a loss of 91 cents per share. Wall Street expected results to range from $-1.12 to -70 cents per share.
Revenue fell 59.4% to $20.16 million from a year ago; analysts expected $24.05 million. 
Ginkgo Bioworks Holdings, Inc.'s reported EPS for the quarter was a loss of 75 cents​.
The company reported a quarterly loss of $46.71 million.
Ginkgo Bioworks Holdings, Inc. shares had fallen by 5.4% this quarter and gained 12.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 18.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Ginkgo Bioworks Holdings, Inc. is $9.00, about 5.6% below its last closing price of $8.50
This summary was machine generated from LSEG data August 7 at 03:29 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.91
-0.75
Beat
Mar. 31 2026 
-1.08
-1.39
Missed
Dec. 31 2025 
-1.45
-1.41
Beat
Sep. 30 2025 
-1.24
-1.45
Missed